Harbour BioMed’s jury victory in a high profile patent case against Amgen (AMGN) has put fresh legal risk in focus, as the verdict confirmed willful infringement and awarded US$20.2 million in damages.

At a share price of US$344.72, Amgen has seen a 5.21% year to date share price return. Its 1 year total shareholder return of 30.33% and 3 year total shareholder return of 68.20% point to stronger longer term momentum despite recent legal headlines.

If this kind of legal and earnings driven story has your attention, it can be useful to see what is happening across other health related stocks that use AI in their pipelines, so take a look at the 38 healthcare AI stocks

With Amgen trading close to analyst price targets yet screening as materially discounted on some intrinsic measures, the key question is whether this legal setback has created a genuine value opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 2.1% Undervalued

With Amgen last closing at $344.72 against a narrative fair value near $352, the gap is small, but the thesis behind that number is detailed.

Advancements in personalized and targeted therapies, reflected in the robust late-stage pipeline (e.g., MariTide for obesity/type 2 diabetes, Repatha and olpasiran for cardiovascular, multiple bispecific T-cell engagers for oncology), position Amgen to launch high-margin, first-in-class products that drive both top-line growth and margin expansion in the coming years.

Curious what growth profile and margin path sit behind that fair value for Amgen? The narrative leans on modest top line expansion, firmer profitability, and a richer future earnings multiple tied to that pipeline potential.

Result: Fair Value of $352.23 (UNDERVALUED)

However, this Amgen narrative still carries real risk if drug pricing pressure tightens further or if biosimilar competitors erode revenue in key franchises faster than expected.

Next Steps

With sentiment on Amgen split between legal risk and pipeline-driven potential, move quickly, review the key data, and weigh the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Amgen?

Do not stop with Amgen. Broaden your watchlist using focused stock ideas that highlight quality, resilience, and income potential before the next wave of opportunities moves past you.

• Spot potential high yield payers early by checking out 7 dividend fortresses, built for investors who want income to play a bigger role in total returns.
• Zero in on sturdier balance sheets with the solid balance sheet and fundamentals stocks screener (48 results) so you can focus on companies that may better withstand tougher conditions.
• Unearth underfollowed opportunities through the screener containing 19 high quality undiscovered gems before they appear on every investor's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.